Navigation Links
Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
Date:9/14/2009

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Thomas McCourt has joined the Company as chief commercial officer and senior vice president of marketing and sales. Mr. McCourt will be responsible for overall commercial strategy and execution and will lead Ironwood's growing marketing and sales team.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

Mr. McCourt comes to Ironwood from Amgen, where he led the U.S. brand team for denosumab, a novel biologic under review at the FDA for the treatment of bone diseases and Amgen's first potential primary care product. Previously, he was with Novartis, where he directed the launch and growth of Zelnorm(R) for the treatment of patients with IBS-C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck, leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec(R), the blockbuster therapy for the treatment of gastroesophageal reflux disease. Mr. McCourt has a degree in pharmacy from the University of Wisconsin.

"We are very pleased that Tom has joined our team," said Peter Hecht, CEO of Ironwood. "Tom's unique knowledge of gastrointestinal product marketing and his multiple experiences bringing breakthrough medicines to the market will be invaluable as we and our partners prepare to bring linaclotide to IBS-C and chronic constipation patients around the world."

"It's wonderful to be at Ironwood. I am impressed with the quality of the people and the high level of science," said Mr. McCourt. "I am extremely excited to have the opportunity to help bring innovative products and therapeutic solutions to patients in need."

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, the Company's first-in-class compound, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood has raised $306 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com


'/>"/>
SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microbia Announces Name Change to Ironwood Pharmaceuticals
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
(Date:2/11/2016)... Texas , Feb. 11, 2016  Vermillion, Inc. ... on gynecologic disease, today announced the formation of the ... --> --> Pelvic masses ... both diagnosis and management. Once pregnancy is ruled out, ... tubes and ovaries, advanced endometriosis, benign ovarian tumors and ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
Breaking Biology Technology:
(Date:2/9/2016)... 9, 2016 Vigilant Solutions announces today that an ... to develop a lead in a difficult homicide case. The ... to locate the suspect vehicle. Due to the ongoing investigation, ... been omitted at the agency,s request. --> ... "Our victim was found deceased at an intersection here in ...
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
Breaking Biology News(10 mins):